[To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Zhang XS, Liu BC, Du X, Zhang YL, Xu N, Liu XL, Li WM, Lin H, Liang R, Chen CY, Huang J, Yang YF, Zhu HL, Pan L, Wang XD, Li GH, Liu ZG, Zhang YQ, Liu ZF, Hu JD, Liu CS, Li F, Yang W, Meng L, Han YQ, Lin LE, Zhao ZY, Tu CQ, Zheng CF, Bai YL, Zhou ZP, Chen SN, Qiu HY, Yang LJ, Sun XL, Sun H, Zhou L, Liu ZL, Wang DY, Guo JX, Pang LP, Zeng QS, Suo XH, Zhang WH, Zheng YJ, Jiang Q.
Zhang XS, et al. Among authors: yang lj, yang yf, yang w.
Zhonghua Xue Ye Xue Za Zhi. 2023 Sep 14;44(9):728-736. doi: 10.3760/cma.j.issn.0253-2727.2023.09.005.
Zhonghua Xue Ye Xue Za Zhi. 2023.
PMID: 38049316
Free PMC article.
Chinese.